证券代码：301122 证券简称：采纳股份 公告编号：2025-086 采纳科技股份有限公司 关于全资子公司取得专利证书的公告 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 2025 年 10 月 9 日 1 / 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）全资子公司江苏采纳医疗科技 有限公司（以下简称"采纳医疗"），于近日收到国家知识产权局颁发的专利证 书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 一次性使用人体动 | 实用新型 | ZL | 采纳医疗 | 2025年09月 | | | 脉血样采集器 | | 202422368179.8 | | 30 日 | 上述专利为公司自主研发，其所涉及技术均与公司主营业务 ...

南财智讯9月29日电，采纳股份发布公告称，子公司近日收到国家知识产权局颁发的1项《实用新型专利 证书》。专利名称为"定量自锁注射器"。 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-085 采纳科技股份有限公司 关于全资子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）全资子公司江苏采纳医疗科技 有限公司（以下简称"采纳医疗"），于近日收到国家知识产权局颁发的专利证 书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 定量自锁注射器 | 实用新型 | ZL | 采纳医疗 | 2025年09月 | | | | | 202421896573.2 | | 26 日 | 上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关， 专利权自授权公告之日起生效。 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 特此公告。 采纳科技股份有限公司董事会 2025 年 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-084 采纳科技股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）召开的第三届董事会第十二次 会议、第三届监事会第十一次会议、2025 年第一次临时股东大会，分别审议通 过了《关于使用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司 及全资子公司在确保不影响募集资金投资项目和公司正常经营，并有效控制风险 的前提下，使用额度不超过人民币 20,000 万元（含本数）的闲置募集资金（含 超募资金）和额度不超过人民币 80,000 万元（含本数）的自有资金进行现金管 理。使用期限自股东大会审议通过之日起 12 个月内有效。在上述额度和期限内， 资金可循环滚动使用。 同时，在额度范围内授权公司管理层行使相关投资决策权并签署相关文件， 具 体 由 公 司 财 务 部 负 责 组 织 实 施 。 具 体 内 容 详 见 公 司 在 巨 潮 资 讯 网 （www.cninfo.com.cn）披露的相关公告。 ...

Core Viewpoint - The company proposes a share award plan in accordance with Chapter 17 of the listing rules, aimed at aligning the interests of eligible participants with those of the group [1] Summary by Relevant Sections - **Share Award Plan**: The plan allows the company to incentivize eligible participants for their contributions or potential contributions to the group through the granting of awards [1] - **Incentive Alignment**: The plan is designed to ensure that the interests of participants are aligned with the interests of the group, providing a tailored incentive mechanism beyond the existing share option plan [1] - **Issuance Limits**: The total number of shares that may be issued under the plan and any other share plans, including existing share option plans, is capped at 10% of the company's issued share capital as of the adoption date; within this limit, the number of shares that may be awarded to service providers is capped at 1% of the total issued shares as of the adoption date [1]

根据计划及任何其他股份计划( 包括但不限于现有购股权计划 )将授予的所有奖励及购股权而可能发行 的股份数目上限合共不得超过采纳日期公司已发行股本的10%;而在该限额内，根据计划及任何其他股 份计划将授予服务供应商的所有奖励及购股权而可能发行的股份数目上限合共不得超过采纳日期已发行 股份总数的1 %。 计划将使公司能够透过授予奖励的方式，向合资格参与者就其对集团作出的贡献或潜在贡献提供激励， 并使彼等的利益与集团的利益保持一致。除现有购股权计划外，公司授予奖励的能力为公司提供了另一 种更贴合每位合资格参与者需求的激励方式。 智通财经APP讯，新火科技控股(01611)公布，董事会建议采纳一项符合上市规则第17章的股份奖励计 划。 ...

格隆汇9月26日丨新火科技控股(01611.HK)公告，董事会建议采纳一项符合上市规则第17章的股份奖励 计划。 根据计划及任何其他股份计划(包括但不限于现有购股权计划)将授予的所有奖励及购股权而可能发行的 股份数目上限合共不得超过采纳日期公司已发行股本的10%；而在该限额内，根据计划及任何其他股份 计划将授予服务供应商的所有奖励及购股权而可能发行的股份数目上限合共不得超过采纳日期已发行股 份总数的1%。 计划将使公司能够透过授予奖励的方式，向合资格参与者就其对集团作出的贡献或潜在贡献提供激励， 并使彼等的利益与集团的利益保持一致。除现有购股权计划外，公司授予奖励的能力为本公司提供了另 一种更贴合每位合资格参与者需求的激励方式。 ...

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, while benefiting from the depreciation of the RMB due to its significant overseas revenue. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][8] - The company began supplying IVF culture tube products to Thermo Fisher in 2018 [3] - As of September 19, the number of shareholders in Canar Medical is 6,901, a decrease of 11.17% from the previous period, while the average circulating shares per person increased by 12.58% [8] Group 2: Financial Performance - For the first half of 2025, Canar Medical reported revenue of 158 million yuan, a year-on-year decrease of 18.54%, and a net profit attributable to shareholders of 9.37 million yuan, down 71.78% year-on-year [8] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed in the last three years [9] Group 3: Market Dynamics - The stock price of Canar Medical fell by 1.25% on September 26, with a trading volume of 48.14 million yuan and a turnover rate of 2.60%, bringing the total market value to 2.99 billion yuan [1] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [4] Group 4: Technical Analysis - The average trading cost of the stock is 23.47 yuan, with recent rapid outflows of shares, suggesting a recommendation for portfolio adjustment [7] - The current stock price is approaching a resistance level of 24.88 yuan, indicating potential for a pullback unless this level is broken [7]

Core Viewpoint - The company, Canar Technology Co., Ltd., has experienced a decline in stock price and financial performance, indicating potential challenges in its operations and market position [1][2]. Group 1: Stock Performance - On September 25, Canar's stock fell by 2.86%, with a trading volume of 54.56 million yuan [1]. - The margin trading data shows a net margin buy of -4.36 million yuan on the same day, with a total margin balance of 78.01 million yuan, accounting for 2.58% of the circulating market value [1]. - The margin balance is above the 90th percentile level over the past year, indicating a high level of margin trading activity [1]. Group 2: Financial Performance - For the first half of 2025, Canar reported a revenue of 158 million yuan, a year-on-year decrease of 18.54% [2]. - The net profit attributable to shareholders was 9.37 million yuan, reflecting a significant year-on-year decline of 71.78% [2]. - Since its A-share listing, Canar has distributed a total of 155 million yuan in dividends, with 122 million yuan distributed over the past three years [2]. Group 3: Company Overview - Canar Technology Co., Ltd. was established on July 23, 2004, and went public on January 26, 2022 [1]. - The company's main business involves the research, production, and sales of medical and veterinary injection and puncture instruments, as well as laboratory consumables [1]. - The revenue composition includes 45.17% from syringes, 45.01% from puncture needles, 5.49% from laboratory consumables, and 4.33% from other sources [1].

Investment Rating - The report recommends focusing on leading companies in various segments of the high-value consumables and medical device sectors, indicating a positive outlook for recovery and growth in these areas [4][30]. Core Insights - High-value consumables have begun to recover from the impacts of centralized procurement, with leading companies regaining profitability levels seen before the procurement initiatives [4][32]. - The medical device and IVD sectors are expected to show signs of recovery, with significant improvements anticipated in financial performance by Q3 2025 for device companies and by Q4 2025 for IVD companies [4][30]. - The report highlights specific high-growth segments, including vascular intervention, orthopedics, and IVD, suggesting that these areas will continue to attract investment due to their growth potential and market dynamics [4][30]. Summary by Sections Medical Devices - The medical device sector is projected to experience a revenue decline in 2024, with a further drop of -5.18% expected in the first half of 2025, but recovery is anticipated thereafter [9][12]. - Despite revenue challenges, the overall gross margin and net profit margin have remained stable, with R&D expenses increasing from approximately 7% pre-pandemic to around 10% currently [10][12]. - Companies in the imaging equipment segment are expected to see improved performance in Q3 2025 as inventory issues are resolved and new procurement projects are executed [13][18]. High-Value Consumables - The high-value consumables sector has shown revenue growth in the first half of 2025, indicating a recovery from previous declines, with profit margins returning to levels seen in 2021 [32][33]. - Specific segments such as vascular intervention and orthopedics are highlighted for their resilience and growth potential, with companies like Huatai Medical and Weigao Orthopedics showing significant revenue increases [38][43]. IVD and Other Segments - The IVD sector is expected to see improvements by Q4 2025, with overall industry recovery projected for the first half of 2026 [4][30]. - The report emphasizes the importance of innovation and market expansion for companies in the rehabilitation and home medical device sectors, with firms like Sanofi and Kefu Medical showing strong growth despite market challenges [24][26].